While the HER2-positive cancers are usually treated with anti-HER2 monoclonal antibodies, exemplified by trastuzumab and pertuzumab, only a fraction of cancers are sensitive to this treatment, and resistance develops frequently (23). This evidence concerns the gene ERBB2 and cancer.